Odonate Therapeutics, Inc. (ODTC)

OTCMKTS: ODTC · Delayed Price · USD
1.48
0.00 (0.00%)
Jun 24, 2022 4:00 PM - Market closed

Company Description

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.

It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer.

The company was founded in 2013 and is based in New York, New York.

Odonate Therapeutics, Inc.
Country United States
Founded 2013
IPO Date Dec 7, 2017
Industry Biotechnology
Sector Health Care
Employees 137

Contact Details

Address:
4747 Executive Dr
San Diego, California 92121-3095
United States
Phone 332 206 0935
Website odonate.com

Stock Details

Ticker Symbol ODTC
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001717452

Key Executives

Name Position
Kevin C. Tang Chairman and Chief Executive Officer
Michael S. Hearne Chief Financial Officer and Principal Accounting Officer
Ryan Cole Senior Vice President of Operations
Dr. Steven S. Pfeiffer Ph.D. Senior Vice President of Technical Operations
Thomas Wei Chief Scientific Officer
Stewart M. Kroll Chief Development Officer
Tracey McKennon Senior Vice President of Quality Assurance
Jennifer Schroeder Senior Vice President of Program Management and Technology
Kim Ma Senior Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
Feb 14, 2022 SC 13G/A Statement of acquisition of beneficial ownership by individuals
Feb 10, 2022 SC 13G/A Statement of acquisition of beneficial ownership by individuals
Feb 7, 2022 15-12B Securities registration termination [Section 12(b)]
Jan 31, 2022 EFFECT Notice of Effectiveness
Jan 31, 2022 EFFECT Notice of Effectiveness
Jan 31, 2022 EFFECT Notice of Effectiveness
Jan 28, 2022 SC 13G/A Statement of acquisition of beneficial ownership by individuals
Jan 28, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 26, 2022 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jan 26, 2022 POS AM Post-Effective amendments for registration statement